Kiora Pharmaceuticals (NASDAQ:KPRX) Issues Quarterly Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) issued its quarterly earnings results on Friday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.72) by $0.73, Zacks reports.

Kiora Pharmaceuticals Price Performance

NASDAQ:KPRX traded up $0.01 on Friday, hitting $2.33. The company’s stock had a trading volume of 11,622 shares, compared to its average volume of 51,811. Kiora Pharmaceuticals has a one year low of $2.21 and a one year high of $4.18. The stock has a fifty day moving average of $2.62 and a two-hundred day moving average of $2.85.

Analysts Set New Price Targets

KPRX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a research report on Tuesday, September 2nd. Zacks Research cut Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Friday, October 31st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kiora Pharmaceuticals has an average rating of “Hold” and an average price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.